Lenalidomide is a novel immunomodulatory agent with a unique dual mechanism of action: its tumoricidal effect leads to direct tumor cell death, and its immunomodulatory effect keeps the tumor in remission. Phase III clinical trials have demonstrated that in patients with relapsed/ refractory multipl
β¦ LIBER β¦
Apomorphine: an update of clinical trial results
β Scribed by Heaton, J P W
- Book ID
- 110041789
- Publisher
- Nature Publishing Group
- Year
- 2000
- Tongue
- English
- Weight
- 188 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0955-9930
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Lenalidomide: an update on evidence from
β
Meletios-Athanassios Dimopoulos; Evangelos Terpos
π
Article
π
2010
π
Elsevier Science
π
English
β 110 KB
Key issues from the clinical trials of a
β
Jeremy P. W. Heaton
π
Article
π
2001
π
Springer-Verlag
π
English
β 95 KB
New oral Xa and IIa inhibitors: updates
β
Sylvia Haas
π
Article
π
2007
π
Springer US
π
English
β 255 KB
Gene therapy clinical trials worldwide t
β
Michael L. Edelstein; Mohammad R. Abedi; Jo Wixon
π
Article
π
2007
π
John Wiley and Sons
π
English
β 574 KB
## Abstract To date, over 1340 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. In 1997 we set up a database to bring together global information on gene therapy clinical trials as comprehensively as possible. The data are compiled and regularly update
215 RTOG: Updated results of randomized
β
James D. Cox
π
Article
π
1996
π
Elsevier Science
π
English
β 132 KB
Update on Clinical Trials of Cardiac Pac
β
Kenneth A. Ellenbogen; David M. Gilligan; Richard K. Shepard
π
Article
π
2000
π
Springer
π
English
β 48 KB